CTLA4 and cancer: A major recent advance in the treatment of human cancer involves the therapeutic targeting of immune response ‘checkpoints’ via antibodies that interfere with cytotoxic T lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptors and their ligands (reviewed in ref.44).